Keyphrases
Advanced Stage Disease
16%
Alemtuzumab
16%
Anecdotal Evidence
16%
Antimicrobial Therapy
16%
Aspergillus Infection
16%
Characteristic Spectrum
16%
Chlorambucil
33%
Chronic Lymphocytic Leukemia
100%
Cytomegalovirus Infection
16%
Cytomegalovirus Reactivation
16%
Disease Process
16%
Disease Response
16%
Fludarabine
33%
Gram-positive
16%
Hemoglobin
16%
Herpesvirus Infection
16%
Hypogammaglobulinemia
16%
Immune Defect
16%
Immunoglobulin Replacement
16%
Immunosuppression
16%
Infection Management
16%
Infection Prevention
16%
Infection Risk
16%
Infection Site
16%
Infectious Complications
100%
Leukemia Therapy
33%
Major Infections
16%
Opportunistic Infections
16%
Pathogenesis of Infection
33%
Pneumocystis Infection
16%
Primary Disease
16%
Purine Analogues
16%
Recurrent Infection
16%
Respiratory Tract
16%
Response to Therapy
16%
Serum Creatinine
16%
Serum IgG
16%
Specific Treatment
16%
T Cells
16%
Therapeutic Advances
16%
Therapeutic Management
16%
Therapy Response
16%
Therapy-related
16%
Treatment Agent
16%
Treatment Strategy
16%
Treatment Trials
16%
Trial Reporting
16%
Vaccination
16%
Pharmacology, Toxicology and Pharmaceutical Science
Alemtuzumab
9%
Antimicrobial Therapy
9%
Aspergillosis
9%
Chlorambucil
18%
Chronic Lymphatic Leukemia
100%
Creatinine
9%
Cytomegalovirus
9%
Cytomegalovirus Infection
9%
Disease
27%
Fludarabine
18%
Herpes Virus Infection
9%
Immune Deficiency
9%
Immunoglobulin
9%
Immunoglobulin Deficiency
9%
Infection
100%
Infectious Complication
100%
Opportunistic Infection
9%
Pneumocystosis
9%
Purine
9%
Purine Derivative
9%
Recurrent Infection
9%
Respiratory Tract
9%